Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients
NCT ID: NCT02390687
Last Updated: 2017-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
31 participants
INTERVENTIONAL
2015-04-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There have been significant changes with respect to the effectiveness of, and attitudes towards conventional antimicrobial therapy to combat disease. With the threat of widespread antibiotic resistance rendering many antibiotics useless against important diseases, there is an increased necessity not only to minimise antibiotic use and develop novel non-antibiotic-based treatments, but also to raise the profile of disease prevention. One approach that has gained interest over recent years is the use of probiotic bacteria for oral applications. The rationale for their use in oral health care stems from the increase in evidence that supports their claims for benefit for a range of diseases. Lactobacilli play an important role in the maintenance of health by stimulating the natural immunity as well as by contributing to the balance of the microflora, by interacting with the other members of the flora. The application of health promoting bacteria for therapeutic purposes, is one of the strongest emerging fields. Time has come to shift the paradigm of the treatment from specific bacteria elimination to alteration of the bacterial ecology by using probiotics.
So the purpose of this study is to discover a more promising approach for the treatment of chronic periodontitis .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers
NCT02329353
Effect of Probiotic Lozenge on Gingivitis and Periodontitis
NCT02203812
To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases Via Modulating the Oral Microbiota
NCT04190485
Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis
NCT02174757
Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.
NCT02121665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Arm
Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Placebo
Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Probiotic Arm
L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
Probiotic
Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
Placebo
Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Need of phase 1 therapy
* Pocket probing depth (PPD) of ≥ 5 mm \< 7 mm at two and/or more sites
* Patients with no history of allergies to the drugs to be used
Exclusion Criteria
* Patients with any systemic diseases
* Patients with history of any periodontal therapy within 6 months to trial
35 Years
49 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KVG Medical College and Hospital
OTHER
Next Gen Pharma India Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mudnoor M Dayakar, MDS
Role: PRINCIPAL_INVESTIGATOR
KVG Medical College & Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Periodontics, K.V.G. College & Hospital,
Kurunjibhag, Sullia (d.k.), Karnataka, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUL_PERIO-RG_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.